Other disorders of pancreatic internal secretion (E16)
The ICD-10 code section E16 covers various other disorders of pancreatic internal secretion, which involve abnormal hormone secretion or related metabolic issues from the pancreas. These codes help specify different forms of hypoglycemia and hormone secretion abnormalities not categorized under diabetes.
This category includes specific codes like E16.0 for drug-induced hypoglycemia without coma, often called iatrogenic or medication-related hypoglycemia. E16.1 identifies other hypoglycemia such as functional hyperinsulinism or postprandial hypoglycemia, with many related synonyms like reactive hypoglycemia and familial hyperinsulinemic hypoglycemia. The unspecified hypoglycemia is captured by E16.2. Increased secretion disorders, such as glucagon excess (E16.3) and increased gastrin secretion (E16.4), include conditions like gastrinoma and Zollinger-Ellison syndrome. Other specified pancreatic secretion disorders fall under E16.8, and unspecified cases are coded as E16.9. This section also addresses hypoglycemia severity levels with codes like E16.A1 to E16.A3. Understanding these codes is essential for accurately coding and managing diverse non-diabetic pancreatic endocrine disorders in clinical practice.
Endocrine, nutritional and metabolic diseases (E00–E89)
Other disorders of glucose regulation and pancreatic internal secretion (E15-E16)
E16 Other disorders of pancreatic internal secretion
- E16.0 Drug-induced hypoglycemia without coma
- E16.1 Other hypoglycemia
- E16.2 Hypoglycemia, unspecified
- E16.3 Increased secretion of glucagon
- E16.4 Increased secretion of gastrin
- E16.8 Other specified disorders of pancreatic internal secretion
- E16.9 Disorder of pancreatic internal secretion, unspecified
E16.A Hypoglycemia level
- E16.A1 Hypoglycemia level 1 NEW CODE
- E16.A2 Hypoglycemia level 2 NEW CODE
- E16.A3 Hypoglycemia level 3 NEW CODE
Other disorders of pancreatic internal secretion (E16)
Clinical Terms
The following clinical terms provide additional context, helping users better understand the clinical background and common associations for each diagnosis listed in this section. Including related terms alongside ICD-10-CM codes supports coders, billers, and healthcare professionals in improving accuracy, enhancing documentation, and facilitating research or patient education.
Carbamoyl-Phosphate Synthase I Deficiency Disease
A urea cycle disorder manifesting in infancy as lethargy, emesis, seizures, alterations of muscle tone, abnormal eye movements, and an elevation of serum ammonia. The disorder is caused by a reduction in the activity of hepatic mitochondrial CARBAMOYL-PHOSPHATE SYNTHASE (AMMONIA). (Menkes, Textbook of Child Neurology, 5th ed, pp50-1)
Congenital Hyperinsulinism
A familial, nontransient HYPOGLYCEMIA with defects in negative feedback of GLUCOSE-regulated INSULIN release. Clinical phenotypes include HYPOGLYCEMIA; HYPERINSULINEMIA; SEIZURES; COMA; and often large BIRTH WEIGHT. Several sub-types exist with the most common, type 1, associated with mutations on an ATP-BINDING CASSETTE TRANSPORTERS (subfamily C, member 8).
Gastrinoma
A GASTRIN-secreting neuroendocrine tumor of the non-beta ISLET CELLS, the GASTRIN-SECRETING CELLS. This type of tumor is primarily located in the PANCREAS or the DUODENUM. Majority of gastrinomas are malignant. They metastasize to the LIVER; LYMPH NODES; and BONE but rarely elsewhere. The presence of gastrinoma is one of three requirements to be met for identification of ZOLLINGER-ELLISON SYNDROME, which sometimes occurs in families with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; (MEN 1).
Hyperammonemia
Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.
Hyperinsulinism
A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS.
Hyperlysinemias
A group of inherited metabolic disorders which have in common elevations of serum LYSINE levels. Enzyme deficiencies of alpha-aminoadipic semialdehyde dehydrogenase and the SACCHAROPINE DEHYDROGENASES have been associated with hyperlysinemia. Clinical manifestations include mental retardation, recurrent emesis, hypotonia, lethargy, diarrhea, and developmental delay. (From Menkes, Textbook of Child Neurology, 5th ed, p56)
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.
Nesidioblastosis
An inherited autosomal recessive syndrome characterized by the disorganized formation of new islets in the PANCREAS and CONGENITAL HYPERINSULINISM. It is due to focal hyperplasia of pancreatic ISLET CELLS budding off from the ductal structures and forming new islets of Langerhans. Mutations in the islet cells involve the potassium channel gene KCNJ11 or the ATP-binding cassette transporter gene ABCC8, both on CHROMOSOME 11.
Rett Syndrome
An inherited neurological developmental disorder that is associated with X-LINKED INHERITANCE and may be lethal in utero to hemizygous males. The affected female is normal until the age of 6-25 months when progressive loss of voluntary control of hand movements and communication skills; ATAXIA; SEIZURES; autistic behavior; intermittent HYPERVENTILATION; and HYPERAMMONEMIA appear. (From Menkes, Textbook of Child Neurology, 5th ed, p199)
